MOTS-c Dosage: What Community Protocols Report
Last updated September 27, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← MOTS-c encyclopedia entry · See also: BPC-157 dosage · Regulatory tracker
MOTS-c is investigational and not FDA approved, and its evidence base is overwhelmingly preclinical (cell and animal studies). There is no label and no validated human dose. The figure below is a community report, documented for education — not instructions for use. An unapproved injectable carries unknowns of identity, purity, and sterility.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
MOTS-c is a mitochondrial-derived peptide — a short peptide encoded within the mitochondrial genome rather than the cell nucleus, which is part of why it is scientifically interesting. In animal studies it acts as a metabolic regulator, activating the cellular energy sensor AMPK and producing effects that have led researchers to describe it as an "exercise mimetic." The honest summary for dosing purposes is that the compelling biology is almost entirely in mice and cells, so any human "dose" is an extrapolation.
What community protocols report
Longevity and biohacker protocols most commonly report the following. It is descriptive, not prescriptive.
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~5–10 mg weekly |
| Frequency | Weekly (sometimes split) |
| Route | Subcutaneous |
| Pattern | Time-limited cycles |
The weekly cadence is convention rather than something established by human pharmacokinetic data, which for MOTS-c is sparse. Because the animal work often involves repeated dosing relative to body weight, naive translation to a fixed human milligram dose is exactly the kind of extrapolation to be skeptical of.
Where MOTS-c stands legally
MOTS-c was on the FDA 503A Category 2 list and, on April 15, 2026, was among the peptides removed from Category 2 (FDA announced the removals that day, effective within seven days; its Category 2 page reflects them as of April 22, 2026) after nominations were withdrawn — which is not approval. On July 23, 2026 the PCAC voted 7–5, with two abstentions, to recommend it for the 503A Bulks List (the vote and FDA's briefing). A recommendation is not a rule: as of September 27, 2026, FDA has not acted on it, and it remains outside the approved-medicine framework; see the Regulatory Status Tracker.
Reconstitution basics
MOTS-c is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before a dose can be measured. The Reconstitution Calculator converts vial strength and diluent volume into an exact syringe draw. As always, a calculator can do the arithmetic but cannot verify that the vial contains what the label claims, or that it is pure and sterile.
Frequently asked questions
Is MOTS-c really an "exercise mimetic"?
That description comes from animal studies showing improved metabolic and exercise-capacity measures. Whether those effects translate to humans at any dose is unproven — it is a research hypothesis, not an established result.
Why weekly dosing?
It is a community convention; robust human pharmacokinetic data that would justify a specific interval are not available.
Is it approved now that it's off Category 2?
No. Removal from Category 2 is procedural, not approval: on July 23, 2026 the PCAC voted 7–5, with two abstentions, to recommend it for the 503A Bulks List, but as of September 27, 2026 FDA has not acted on it, and it is not an approved medicine.
Sources
- Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metab. 2015;21:443–454.
- Reynolds JC, et al. MOTS-c and exercise/metabolic regulation.
- U.S. FDA — 503A bulk drug substances list update and Category 2 removals, April 15, 2026; PCAC meeting notice for July 23–24, 2026.
Medical disclaimer: Education only, not medical advice. MOTS-c is investigational and not approved for human use. Dosing figures reflect community reports, not a recommendation. Do not self-administer; consult a licensed clinician.